Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients…
SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in…